Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 45, Issue 1, 2010, Pages 165-170

  Chevallier, P ^a   Prebet, T ^b   Turlure, P ^c   Hunault, M ^d   Vigouroux, S ^e   Harousseau, J L ^f   Blaise, D ^b   Ifrah, N ^d   Milpied, N ^e   Mohty, M ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE NANTES   (France)

Author keywords

Allo HSCT; CD33; Gemtuzumab; Toxicity; VOD

Indexed keywords

AMSACRINE; BUSULFAN; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HEPARIN; MITOXANTRONE; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; GRANULOCYTIC SARCOMA; HUMAN; HYPERBILIRUBINEMIA; LOW DRUG DOSE; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; TREATMENT OUTCOME; VEIN OCCLUSION;

ADOLESCENT; ADULT; AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPARIN; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 75149161568     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.153     Document Type: Article

References (26)

1. Burnett AK, Kell WJ, Goldstone AH, Milligan D, Hunter A, Prentice AG et al. The addition of Gemtuzumab Ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial. Blood 2006; 108: 8a, abstract 13.
2. Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R et al. Long-term disease-free survival after Gemtuzumab, intermediate-dose cytarabine and Mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukaemia. J Clin Oncol 2008; 26: 5192-5197.
3. Senzolo M, Germani G, Cholongitas E, Burra P, Burroughs AK. Veno occlusive disease: update on clinical management. World J Gastroenterol 2007; 13: 3918-3924.
4. Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33- positive acute myeloid leukemia in first recurrence. Cancer 2005; 104: 1442-1452.
5. Chevallier P, Roland V, Mahe B, Juge-Morineau N, Dubruille V, Guillaume T et al. Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukaemia. Leuk Res 2005; 29: 1003-1007.
6. Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578-1582.
7. Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+acute myeloid aeukemia. Blood 2005; 106: 1183-1188.
8. McDonald G, Hinds M, Fisher L, Schoch HG, Wolford JL, Banaji M et al. Venoocclusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
9. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
10. Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund JF et al. Incidence and outcome of hepatic venoocclusive disease after blood or marrow transplantation: A prospective cohort study of the European group for blood and marrow transplantation. European Group for blood and marrow transplantation chronic leukemia working party. Blood 1998; 92: 3599-3604.
11. Scott BL, Sandmaier BM. Reduced-intensity allogeneic bone marrow transplantation: outcomes with myeloid malignancies. Hematology, (Educational Program, ASH 2006) 2006; 2006: 381-389.
12. Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukaemia. Cancer Chemother Pharmacol 2002; 50: 497-500.
13. Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukaemia: a prospective study of the alfa group. Leukemia 2006; 21: 66-71.
14. Eom KS, Kim HJ, Min WS, Lee S, Min CK, Cho BS et al. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukaemia aged 55 or older. Eur J Haematol 2007; 79: 398-404.
15. Candoni A, Martinelli G, Toffoletti E, Chiarvesio A, Tiribelli M, Malagola M et al. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leuk Res 2008; 32: 1800-1808.
16. Aplenc R, Alonzo TA, Gerbing RB, Lange BJ, Hurwitz CA, Wells RJ et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukaemia: a report from the children 's oncology group. J Clin Oncol 2008; 26: 2390-3295.
17. Brethon B, Yakouben K, Oudot C, Boutard P, Bruno B, Jerome C et al. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Br J Haematol 2008; 143: 541-547.
18. De Lima M, Champlin RE, Thall PF, Wang X, Martin 3rd TG, Cook JD et al. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 2008; 22: 258-264.
19. Bornhauser M, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M et al. Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia. Clin Cancer Res 2008; 14: 5585-5593.
20. Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834-2840.
21. Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Biasolo MA et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005; 90: 1396-1404.
22. Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Goulden N. Prophylaxis with defibrotide prevents venoocclusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004; 103: 1968.
23. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470-476. (Pubitemid 36841962)
24. Van der Velden VH, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 2004; 18: 983-988.
25. McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma 2002; 2: S35-S39.
26. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukaemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099.